Biotechnology Terms Starting With V

Vaccine Adjuvant is a substance added to a vaccine formulation that enhances and modulates the immune response to antigens, improving vaccine efficacy and durability.

Vaccine adjuvants work through multiple mechanisms including forming antigen depots for sustained release, activating innate immune receptors like Toll-like receptors, and recruiting immune cells to injection sites. Aluminum salts, used since the 1930s, remain the most common adjuvants in human vaccines and can increase antibody titers by 10 to 100-fold compared to antigen alone. Modern adjuvants like AS01 in the shingles vaccine Shingrix combine monophosphoryl lipid A and QS-21 saponin to stimulate both cellular and humoral immunity, achieving efficacy rates exceeding 97%.

MF59, a squalene-based oil-in-water emulsion, has been administered to over 100 million people in seasonal influenza vaccines, particularly benefiting elderly populations with weakened immune responses. The choice of adjuvant determines whether a vaccine induces primarily antibody responses, T cell responses, or balanced immunity, making adjuvant selection a defining factor for different pathogen types.

Vector Cloning is the process of inserting foreign DNA fragments into self-replicating genetic elements to amplify and manipulate specific sequences in host cells.

Vector cloning involves cutting both the target DNA and a vector, typically a plasmid, with restriction enzymes that produce compatible ends, then joining them with DNA ligase to create recombinant molecules. Common cloning vectors include pUC19, pBR322, and pET expression plasmids in bacteria, as well as yeast artificial chromosomes that can accommodate DNA inserts exceeding 1 million base pairs. Recombinant vectors are introduced into host cells through transformation or electroporation, and transformed cells are selected using antibiotic resistance genes or colorimetric screening methods like blue-white selection.

Modern techniques such as Gibson Assembly, Gateway cloning, and TOPO cloning eliminate the need for restriction enzymes by using alternative DNA joining mechanisms that improve efficiency and flexibility. Stanley Cohen and Herbert Boyer performed the first successful vector cloning experiment in 1973 using the pSC101 plasmid to transfer antibiotic resistance genes between bacteria, launching the commercial biotechnology industry.

Viral Vector is an engineered virus modified to deliver therapeutic or experimental genetic material into target cells without causing disease.

Common viral vectors include adeno-associated virus, which targets non-dividing tissues such as muscle and retinal cells; lentivirus, which integrates stably into both dividing and non-dividing cells; and adenovirus, which drives transient high-level gene expression without chromosomal integration. Engineers remove the viral genes required for replication and replace them with the therapeutic gene of interest, retaining only the sequences needed for packaging, cell entry, and, in integrating vectors, chromosomal insertion. Cargo capacity differs substantially across vector types: adeno-associated virus accommodates inserts of roughly 4.7 kilobases, while lentiviral vectors can carry up to 8 kilobases of foreign sequence.

Spark Therapeutics’ Luxturna, approved by the FDA in 2017, uses an adeno-associated virus serotype 2 vector to deliver a functional copy of the RPE65 gene directly to retinal cells, restoring vision in patients with inherited retinal dystrophy. Tissue tropism, immunogenicity, and manufacturing scalability remain the primary engineering challenges that determine which vector type suits a given therapeutic application.

Virus-Like Particle is a self-assembling protein structure that mimics the outer shell of a virus but contains no genetic material, making it safe for use in vaccines and other biomedical applications because it stimulates an immune response without causing infection.

Virus-like particles are produced by expressing viral structural proteins in heterologous systems like yeast, insect cells, or mammalian cells, where they spontaneously assemble into particles resembling native virions. The hepatitis B vaccine, one of the most successful vaccines globally, consists entirely of VLPs composed of hepatitis B surface antigen produced in yeast cells, protecting over 1 billion people since its introduction in 1986. VLPs present antigens in repetitive, highly ordered arrays that strongly activate B cells and generate robust antibody responses without the safety concerns of live attenuated or inactivated whole virus vaccines.

Gardasil 9, the human papillomavirus vaccine protecting against nine HPV types, contains VLPs for each viral strain and has achieved nearly 100% efficacy in preventing targeted HPV infections and associated cancers. VLP technology now extends beyond vaccines to drug delivery, gene therapy vectors, and diagnostic applications, with platforms like Novavax’s Matrix-M adjuvanted VLP vaccines showing promise against influenza and SARS-CoV-2.